TG Therapeutics Investor Relations Material

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company's therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; Umbralisib, an oral inhibitor of PI3K delta and CK1 epsilon for the treatment of CLL and follicular lymphoma; Cosibelimab, a human monoclonal antibody that binds to programmed death ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK over ibrutinib in in vitro kinase screening; TG-1801, a bispecific CD47/CD19 antibody generated by fusion technology platform across two distinct proteins each comprising single chain moieties from humanized IgG.